Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 17/20 | 0.76 |
| ▸ | EGFR | P00533 | 7/20 | 0.75 |
| ▸ | TEC | P42680 | 4/20 | 0.73 |
| ▸ | BMX | P51813 | 4/20 | 0.73 |
| ▸ | LYN | P07948 | 3/20 | 0.73 |
| ▸ | ITK | Q08881 | 3/20 | 0.73 |
| ▸ | TXK | P42681 | 2/20 | 0.73 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.73 |
| ▸ | ABL1 | P00519 | 2/20 | 0.73 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.73 |
| ▸ | LCK | P06239 | 2/20 | 0.73 |
| ▸ | FYN | P06241 | 2/20 | 0.73 |
| ▸ | YES1 | P07947 | 2/20 | 0.73 |
| ▸ | HCK | P08631 | 2/20 | 0.73 |
| ▸ | FGR | P09769 | 2/20 | 0.73 |
| ▸ | SRC | P12931 | 2/20 | 0.73 |
| ▸ | FER | P16591 | 2/20 | 0.73 |
| ▸ | CSK | P41240 | 2/20 | 0.73 |
| ▸ | BLK | P51451 | 2/20 | 0.73 |
| ▸ | JAK3 | P52333 | 2/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15155348 | 0.92 | BTK (0.85) | BTKEGFRTECBMXLYN | |
| SCHEMBL15155363 | 0.91 | BTK (0.91) | BTKEGFRTECBMXLYN | |
| SCHEMBL16075019 | 0.86 | BTK (1.00) | BTKEGFRTECBMXLYN | |
| SCHEMBL202187 | 0.86 | BTK (1.00) | BTKEGFRTECBMXLYN | |
| SCHEMBL15155117 | 0.85 | BTK (1.00) | BTKEGFRTECBMXLYN | |
| Ibrutinib SCHEMBL201642 | 0.85 | BTK (1.00) | BTKEGFRTECBMXLYN | |
| Ibrutinib SCHEMBL2244870 | 0.85 | BTK (1.00) | BTKEGFRTECBMXLYN | |
| Ibrutinib SCHEMBL201859 | 0.85 | BTK (1.00) | BTKEGFRTECBMXLYN | |
| Ibrutinib SCHEMBL2244865 | 0.85 | BTK (1.00) | BTKEGFRTECBMXLYN | |
| Ibrutinib SCHEMBL201641 | 0.85 | BTK (1.00) | BTKEGFRTECBMXLYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9458162-B2 | Cyclic molecules as bruton's tyrosine kinase inhibitors | NANJING ALLGEN PHARMA CO. LTD. (CN) | 2016-10-04 | — | — | US | disclosed |
| US-9458162-B2 | Cyclic molecules as bruton's tyrosine kinase inhibitors | NANJING ALLGEN PHARMA CO. LTD. (CN) | 2016-10-04 | — | — | US | disclosed |
| US-20150011530-A1 | CYCLIC MOLECULES AS BRUTON'S TYROSINE KINASE INHIBITORS | GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) | 2015-01-08 | — | — | US | disclosed |
| US-20150011530-A1 | CYCLIC MOLECULES AS BRUTON'S TYROSINE KINASE INHIBITORS | GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011530-A1 | CYCLIC MOLECULES AS BRUTON'S TYROSINE KINASE INHIBITORS | ABL1, BTK, PRKACA | BTK 2/4885EGFR 802/4885TEC 323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.